MedPath
EMA Product

Latuda

Product approved by European Medicines Agency (EU)

Basic Information

Latuda

Regulatory Information

EMEA/H/C/002713

Authorised

March 21, 2014

January 22, 2014

27

December 13, 2024

Company Information

Italy

Viale Amelia 70 00181 Roma

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of schizophrenia in adults aged 18 years and over.

Overview Summary

Latuda is a medicine that is used to treat patients from 13 years of age with schizophrenia, a mental illness with symptoms that include disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Latuda contains the active substance lurasidone.

© Copyright 2025. All Rights Reserved by MedPath